Elanco Animal Health Stock Price, News & Analysis

Elanco Animal Health (NYSE:ELAN) announces FDA approval for Bexacat™ (bexagliflozin tablets), the first oral medication improving glycemic control in diabetic cats. Approximately 600,000 cats in the U.S. are diagnosed with diabetes, with 125,000 untreated due to insulin's complexities. Bexacat offers a non-insulin, once-daily treatment, enhancing convenience for pet owners. In pivotal studies, 83% of treated cats showed improvement by day 56. Bexacat is expected to be available by Q1 2023, enriching Elanco's feline health portfolio alongside other innovative products.

Elanco Animal Health (NYSE: ELAN) announced its participation in the Evercore ISI 5th Annual HealthCONx Conference on November 29, 2022. CEO Jeff Simmons will engage in a fireside chat at 8:50 a.m. Eastern time. A live audio webcast will be accessible via the company’s investor website, with a replay available for 90 days post-event. Elanco, a leader in animal health for nearly 70 years, focuses on innovative solutions for farm animals and pets, committed to enhancing animal health and community impact.

Elanco Animal Health reported Q3 2022 results with revenues of $1,028 million, a 9% decline from last year. Despite challenges, adjusted EPS rose 5% to $0.20. A net loss of $49 million was recorded, improving from $104 million in Q3 2021. The company updated its full-year guidance, forecasting revenue between $4,385 million and $4,430 million. Significant foreign exchange impacts are anticipated, with a loss of around $225 million. Elanco expects five blockbuster product approvals by mid-2024, including a parasiticide and a monoclonal antibody for canine parvovirus.

Elanco Animal Health Incorporated (NYSE: ELAN) will publish its third quarter 2022 financial results on November 8, 2022. Following this, a conference call with investors and media is scheduled for 8:00 a.m. ET to discuss the company’s performance in detail. Participants can access the live webcast through the company's investor relations website. Elanco aims to innovate and deliver products for animal health, enhancing the welfare of animals and providing value across the animal health ecosystem.

Elanco Animal Health (NYSE: ELAN) announced that Scott Ferguson is stepping down from its Board of Directors to focus on other commitments with Sachem Head Capital Management. Ferguson expressed confidence in Elanco's strategy, emphasizing its path to creating shareholder value through cost discipline and innovation. R. David Hoover, chairman of the board, acknowledged Ferguson's contributions during his tenure since December 2020. Jeffrey N. Simmons, CEO, reaffirmed strong strategy execution, promising upcoming innovations that aim to enhance value for customers and shareholders.

Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022. Jeff Simmons, the president and CEO, is scheduled for a fireside chat at 2:50 p.m. Eastern time.

A live audio webcast of the event will be accessible via the company’s investor website, with a replay available for 90 days.

Elanco Animal Health has released its 2021 Environmental, Social and Governance (ESG) Report detailing advances in sustainability and health initiatives. The report highlights efforts in workforce diversity with goals to increase women's leadership representation to 42% by 2023, and People of Color to 20%. Environmental impact is addressed by reducing emissions by 8% since 2020 and transitioning to renewable energy. Elanco also launched a global Animal Welfare Policy and improved access to veterinary care for 20 million farm animals in East Africa.

Elanco Animal Health reported a Q2 2022 revenue of $1,177 million, an 8% decrease year-over-year. The company’s net loss was $22 million, an improvement from $210 million last year. Adjusted net income reached $177 million with an adjusted EPS of $0.36. Full-year revenue guidance is now $4,465 to $4,550 million. Adjusted EBITDA for Q2 was $300 million, with margins improving to 25.5%. Amid macroeconomic challenges, Elanco emphasizes its strong pipeline, including new products set for market launch.

Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2022 financial results on Monday, August 8, 2022. A conference call will take place at 8:00 a.m. eastern time for detailed discussion of its performance. Investors and media can access a live webcast from Elanco's website, with a replay available shortly after the call. Elanco is committed to innovating animal health products and services, enhancing animal health, and delivering value to stakeholders.